CureVac N.V.

Informe acción NasdaqGM:CVAC

Capitalización de mercado: US$619.1m

CureVac Crecimiento futuro

Future controles de criterios 0/6

CureVac is forecast to grow earnings and revenue by 46.3% and 4% per annum respectively. EPS is expected to grow by 49% per annum. Return on equity is forecast to be -15.1% in 3 years.

Información clave

46.3%

Tasa de crecimiento de los beneficios

49.0%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Biotechs27.1%
Tasa de crecimiento de los ingresos4.0%
Rentabilidad financiera futura-15.1%
Cobertura de analistas

Good

Última actualización01 Nov 2024

Actualizaciones recientes sobre el crecimiento futuro

Analysts Have Lowered Expectations For CureVac N.V. (NASDAQ:CVAC) After Its Latest Results

Apr 29
Analysts Have Lowered Expectations For CureVac N.V. (NASDAQ:CVAC) After Its Latest Results

Recent updates

CureVac: Back To Square One

Oct 08

CureVac N.V.'s (NASDAQ:CVAC) Share Price Could Signal Some Risk

Sep 16
CureVac N.V.'s (NASDAQ:CVAC) Share Price Could Signal Some Risk

CureVac N.V.'s (NASDAQ:CVAC) Intrinsic Value Is Potentially 93% Above Its Share Price

Aug 03
CureVac N.V.'s (NASDAQ:CVAC) Intrinsic Value Is Potentially 93% Above Its Share Price

We're Hopeful That CureVac (NASDAQ:CVAC) Will Use Its Cash Wisely

Jul 05
We're Hopeful That CureVac (NASDAQ:CVAC) Will Use Its Cash Wisely

CureVac: GSK's Deal For Infectious Disease Assets Is A Long-Shot For Both Pharmas

Jul 04

Optimistic Investors Push CureVac N.V. (NASDAQ:CVAC) Shares Up 47% But Growth Is Lacking

Jun 01
Optimistic Investors Push CureVac N.V. (NASDAQ:CVAC) Shares Up 47% But Growth Is Lacking

We Think CureVac (NASDAQ:CVAC) Needs To Drive Business Growth Carefully

Mar 20
We Think CureVac (NASDAQ:CVAC) Needs To Drive Business Growth Carefully

CureVac: No Momentum In Sight

Mar 08

What Does The Future Hold For CureVac N.V. (NASDAQ:CVAC)? These Analysts Have Been Cutting Their Estimates

Aug 26
What Does The Future Hold For CureVac N.V. (NASDAQ:CVAC)? These Analysts Have Been Cutting Their Estimates

CureVac N.V.'s (NASDAQ:CVAC) Intrinsic Value Is Potentially 89% Above Its Share Price

Jun 14
CureVac N.V.'s (NASDAQ:CVAC) Intrinsic Value Is Potentially 89% Above Its Share Price

Some Analysts Just Cut Their CureVac N.V. (NASDAQ:CVAC) Estimates

May 01
Some Analysts Just Cut Their CureVac N.V. (NASDAQ:CVAC) Estimates

Analysts Have Lowered Expectations For CureVac N.V. (NASDAQ:CVAC) After Its Latest Results

Apr 29
Analysts Have Lowered Expectations For CureVac N.V. (NASDAQ:CVAC) After Its Latest Results

An Intrinsic Calculation For CureVac N.V. (NASDAQ:CVAC) Suggests It's 46% Undervalued

Jan 08
An Intrinsic Calculation For CureVac N.V. (NASDAQ:CVAC) Suggests It's 46% Undervalued

CureVac BV reports Q2 results

Aug 18

CureVac claims patent rights for Pfizer/BioNTech COVID-19 vaccine

Jul 05

Will CureVac (NASDAQ:CVAC) Spend Its Cash Wisely?

May 29
Will CureVac (NASDAQ:CVAC) Spend Its Cash Wisely?

Analysts Are Betting On CureVac N.V. (NASDAQ:CVAC) With A Big Upgrade This Week

May 02
Analysts Are Betting On CureVac N.V. (NASDAQ:CVAC) With A Big Upgrade This Week

A Look At The Intrinsic Value Of CureVac N.V. (NASDAQ:CVAC)

Oct 28
A Look At The Intrinsic Value Of CureVac N.V. (NASDAQ:CVAC)

CureVac: Wait For Concrete News Before Investing

Sep 01

CureVac plunges as COVID-19 vaccine candidate indicates below par efficacy

Jun 16

An Intrinsic Calculation For CureVac N.V. (NASDAQ:CVAC) Suggests It's 31% Undervalued

Jun 13
An Intrinsic Calculation For CureVac N.V. (NASDAQ:CVAC) Suggests It's 31% Undervalued

CureVac tumbles on potential delay for European decision on its COVID-19 shot

Jun 08

CureVac: The Moment Of Truth Arrives

Jun 01

CureVac BV reports Q1 results

May 26

CureVac Could Soon Join The Fight Against COVID-19

May 10

CureVac N.V.'s (NASDAQ:CVAC) Has Found A Path To Profitability

May 02
CureVac N.V.'s (NASDAQ:CVAC) Has Found A Path To Profitability

Previsiones de crecimiento de beneficios e ingresos

NasdaqGM:CVAC - Estimaciones futuras de los analistas y datos financieros pasados (EUR Millions)
FechaIngresosBeneficiosFlujo de caja libreFlujo de caja operativoNúm. de analistas medio
12/31/2026113-75-21N/A5
12/31/202573-10444N/A7
12/31/2024178-11021N/A6
6/30/202466-278-330-290N/A
3/31/202459-273-312-265N/A
12/31/202354-260-323-268N/A
9/30/202343-302-335-273N/A
6/30/202338-301-325-249N/A
3/31/202350-291-338-249N/A
12/31/202267-249-379-286N/A
9/30/202297-122-527-420N/A
6/30/2022115-219-758-659N/A
3/31/2022117-313-782-673N/A
12/31/2021103-412-861-733N/A
9/30/202168-468-228-109N/A
6/30/202144-361N/AN/AN/A
3/31/202156-219250329N/A
12/31/202049-129475522N/A
9/30/202050-1073662N/A
3/31/202017-102-82-67N/A
12/31/201917-100-99-87N/A
12/31/201813-71-89-74N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: CVAC is forecast to remain unprofitable over the next 3 years.

Beneficios vs. Mercado: CVAC is forecast to remain unprofitable over the next 3 years.

Beneficios de alto crecimiento: CVAC is forecast to remain unprofitable over the next 3 years.

Ingresos vs. Mercado: CVAC's revenue (4% per year) is forecast to grow slower than the US market (8.9% per year).

Ingresos de alto crecimiento: CVAC's revenue (4% per year) is forecast to grow slower than 20% per year.


Previsiones de crecimiento de los beneficios por acción


Rentabilidad financiera futura

ROE futura: CVAC is forecast to be unprofitable in 3 years.


Descubre empresas en crecimiento